Verdence Capital Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.04M | Buy |
179,591
+37
| +0% | +$985 | 0.29% | 78 |
|
|
2025
Q4 | $4.47M | Sell |
179,554
-7,096
| -4% | -$179K | 0.26% | 91 |
|
|
2025
Q3 | $4.62M | Buy |
186,650
+35,502
| +23% | +$876K | 0.27% | 90 |
|
|
2025
Q2 | $3.66M | Buy |
151,148
+26,354
| +21% | +$615K | 0.25% | 97 |
|
|
2025
Q1 | $3.16M | Buy |
124,794
+11,154
| +10% | +$292K | 0.24% | 101 |
|
|
2024
Q4 | $3.01M | Sell |
113,640
-14,555
| -11% | -$395K | 0.24% | 108 |
|
|
2024
Q3 | $3.71M | Sell |
128,195
-540
| -0.4% | -$15.8K | 0.3% | 83 |
|
|
2024
Q2 | $3.6M | Sell |
128,735
-3,531
| -3% | -$97.2K | 0.32% | 73 |
|
|
2024
Q1 | $3.67M | Buy |
132,266
+12,886
| +11% | +$358K | 0.33% | 73 |
|
|
2023
Q4 | $3.44M | Sell |
119,380
-15,736
| -12% | -$476K | 0.33% | 76 |
|
|
2023
Q3 | $4.48M | Sell |
135,116
-2,468
| -2% | -$87.3K | 0.49% | 48 |
|
|
2023
Q2 | $5.05M | Buy |
137,584
+1,257
| +0.9% | +$48.9K | 0.59% | 42 |
|
|
2023
Q1 | $5.56M | Buy |
136,327
+3,059
| +2% | +$132K | 0.67% | 31 |
|
|
2022
Q4 | $6.83M | Sell |
133,268
-7,312
| -5% | -$351K | 0.84% | 21 |
|
|
2022
Q3 | $6.15M | Buy |
140,580
+1,718
| +1% | +$83.5K | 0.85% | 21 |
|
|
2022
Q2 | $7.28M | Sell |
138,862
-4,361
| -3% | -$222K | 0.94% | 16 |
|
|
2022
Q1 | $7.42M | Buy |
143,223
+23,126
| +19% | +$1.2M | 0.84% | 19 |
|
|
2021
Q4 | $7.09M | Sell |
120,097
-5,387
| -4% | -$267K | 0.83% | 25 |
|
|
2021
Q3 | $5.4M | Sell |
125,484
-9,079
| -7% | -$402K | 0.71% | 31 |
|
|
2021
Q2 | $5.27M | Buy |
134,563
+68,883
| +105% | +$2.68M | 0.73% | 29 |
|
|
2021
Q1 | $2.38M | Sell |
65,680
-5,069
| -7% | -$180K | 0.4% | 68 |
|
|
2020
Q4 | $2.6M | Sell |
70,749
-8,354
| -11% | -$306K | 0.49% | 47 |
|
|
2020
Q3 | $2.75M | Sell |
79,103
-2,877
| -4% | -$101K | 0.63% | 39 |
|
|
2020
Q2 | $2.54M | Sell |
81,980
-93,328
| -53% | -$3.17M | 0.63% | 37 |
|
|
2020
Q1 | $5.43M | Buy |
175,308
+52,434
| +43% | +$1.79M | 1.62% | 10 |
|
|
2019
Q4 | $4.57M | Sell |
122,874
-15,829
| -11% | -$564K | 1.12% | 19 |
|
|
2019
Q3 | $4.73M | Buy |
138,703
+14,825
| +12% | +$539K | 1.33% | 11 |
|
|
2019
Q2 | $5.09M | Sell |
123,878
-16,427
| -12% | -$652K | 1.46% | 10 |
|
|
2019
Q1 | $5.65M | Sell |
140,305
-115,354
| -45% | -$4.62M | 1.53% | 11 |
|
|
2018
Q4 | $10.6M | Sell |
255,659
-30,061
| -11% | -$1.25M | 2.96% | 2 |
|
|
2018
Q3 | $11.9M | Sell |
285,720
-22,839
| -7% | -$879K | 2.96% | 2 |
|
|
2018
Q2 | $10.6M | Sell |
308,559
-4,858
| -2% | -$166K | 2.58% | 2 |
|
|
2018
Q1 | $10.6M | Sell |
313,417
-1,569
| -0.5% | -$53.9K | 2.54% | 3 |
|
|
2017
Q4 | $10.8M | Buy |
+314,986
| New | +$10.7M | 2.58% | 4 |
|
Other funds holding PFE
VCM
VPM
Verdence Capital Advisors's PFE Position: Q1 2026 in Review
Verdence Capital Advisors increased its Pfizer (PFE) stake by 0.02% in Q1 2026, buying an estimated $985 and bringing the position to 179,591 shares worth $5.04M. The position accounts for 0.29% of the portfolio, ranked #78.
Verdence Capital Advisors first reported a position in PFE in Q4 2017 and has held it in 34 quarters since. The position peaked at $11.9M in Q3 2018. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Verdence Capital Advisors held 179,591 shares of Pfizer worth $5.04M as of Q1 2026.
- Verdence Capital Advisors bought 37 Pfizer shares in Q1 2026, an estimated $985.
- Pfizer made up 0.29% of Verdence Capital Advisors's portfolio in Q1 2026, its #78 holding.
- Verdence Capital Advisors first reported a position in Pfizer in Q4 2017 and has held it in 34 quarters since.
- Verdence Capital Advisors's Pfizer position peaked at $11.9M in Q3 2018.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Verdence Capital Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.